Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. (May 2017)

• Record Type: Journal Article
• Authors: Kwakman, Johannes J.M.; Simkens, Lieke H.J.; Mol, Linda; Kok, Wouter E.M.; Koopman, Miriam; Punt, Cornelis J.A.
• Is Part Of: European journal of cancer. Volume 76(2017)
• Page Start: 93
• Page End: 99
• Publication Date: 2017-05
• Subjects: Capecitabine -- Cardiotoxicity -- Retrospective analysis; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2017.02.009
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Background: The frequency of capecitabine-related cardiotoxicity has been reported to be low but includes serious adverse events. We conducted a retrospective analysis of the incidence and severity of capecitabine-related cardiotoxicity in different regimens in the treatment of metastatic colorectal cancer in three randomised phase 3 studies. Methods: We used data of cardiac events reported in the CAIRO, CAIRO2 and CAIRO3 studies of the Dutch Colorectal Cancer Group (DCCG) and analysed the incidence and severity of cardiac events in the different treatment regimens of the trials which all included the use of capecitabine. The following events were included: chest pain, newly diagnosed cardiac ischaemia/infarction, atrial fibrillation, other arrhythmias and heart failure, all graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC). Results: A total of 1973 patients were included, who received a total of 2461 capecitabine-based lines of treatment. Overall, 5.9% of patients ( n = 117) experienced at least one cardiac event, and 2.3% ( n = 46) experienced at least one grade ≥3 event. Three patients had two cardiac events. The most frequently observed cardiac event was ischaemia/infarction (2.9%, n = 57), followed by arrhythmias (2.0%, n = 40, including atrial fibrillation in 10 patients), chest pain (0.8%, n = 16) and heart failure (0.4%, n = 7). The highest incidence of cardiac events was observed in patients treated with capecitabine in combination with oxaliplatin and bevacizumab (12%, n = 43). Conclusion: We observed capecitabine-related cardiotoxicity in 5.9% of patients, and severe cardiotoxicity in 2.3% of patients. Combination treatment with capecitabine, oxaliplatin and bevacizumab was associated with the highest risk of cardiotoxicity. Highlights: In this largest retrospective analysis to date, we observed cardiotoxicity in 5.9% of patients. The incidence of grade ≥3 cardiac events was 2.3%. Cardiac ischemia/infarction and cardiac arrhythmias were the most frequently observed cardiac events. Combination treatment with capecitabine, oxaliplatin and bevacizumab was associated with the highest risk of cardiotoxicity. We support a thorough cardiac evaluation in every patient with cardiac symptoms during treatment with capecitabine.